CLPT / ClearPoint Neuro, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

Calculation of Filing Fee Table FORM S-8 (Form Type) ClearPoint Neuro, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Calculation of Filing Fee Table FORM S-8 (Form Type) ClearPoint Neuro, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (4) Maximum Aggregate Offering Price (4) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0

As filed with the Securities and Exchange Commission on September 4, 2025

As filed with the Securities and Exchange Commission on September 4, 2025 Registration No.

ClearPoint Neuro Reports Second Quarter 2025 Results Record Revenue and Substantial Cash Infusion Highlight the Company’s ‘Fast. Forward.’ Strategy

ClearPoint Neuro Reports Second Quarter 2025 Results Record Revenue and Substantial Cash Infusion Highlight the Company’s ‘Fast.

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 CLEARPOINT NEURO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34822 58-2394628 (State or Other Jurisdiction of Incorporation) (Commission

WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY.Nasdaq: CLPTAugust 2025

WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdaq: CLPT August 2025 DISCLAIMER This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company’s expectation for revenues, gross margin, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, the future market of its products a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-34822 ClearPoint

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 CLEARPOINT NEURO, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 CLEARPOINT NEURO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34822 58-2394628 (State or Other Jurisdiction of Incorporation) (Commission Fi

Lease dated as of June 16, 2025, by and between BRE-BMR SCD LLC, a Delaware limited liability company, and ClearPoint Neuro, Inc.

Exhibit 10.1 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LEASE by and between BRE-BMR SCD LLC, a Delaware limited liability company and CLEARPOINT NEURO, INC., a Delaware corporation Table of Contents 1. Lease of Premises 1 2. Basic Lease P

FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Item 5.07 Submission of Matters to a Vote of Security Holders. Item 9.01 Financial S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 CLEARPOINT NEURO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34822 58-2394628 (State or Other Jurisdiction of Incorporation) (Commission Fil

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 CLEARPOINT NEURO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34822 58-2394628 (State or Other Jurisdiction of Incorporation) (Commission Fil

ClearPoint Neuro, Inc. Non-Employee Director Compensation Plan, as amended and restated by the Board of Directors (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on May 19, 2025).

Exhibit 10.1 CLEARPOINT NEURO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PLAN This Non-Employee Director Compensation Plan (this “Plan”) sets forth the compensation for non-employee members of the Board of Directors (the “Board”) of ClearPoint Neuro, Inc. (the “Company”). This Plan applies only to non-employee members of the Board and is not applicable to employee members of the Board. This Plan wil

ClearPoint Neuro Reports First Quarter 2025 Results Record Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products

Exhibit 99.1 ClearPoint Neuro Reports First Quarter 2025 Results Record Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products SOLANA BEACH, CA, May 13, 2025 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first qua

© 2025 CLEARPOINT NEURO WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdaq: CLPT May 2025

© 2025 CLEARPOINT NEURO WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdaq: CLPT May 2025 DISCLAIMER This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company’s expectation for revenues, gross margin, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, the future mar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-34822 ClearPoint

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 CLEARPOINT NEURO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34822 58-2394628 (State or Other Jurisdiction of Incorporation) (Commission Fil

-1-

Exhibit 99.1 May 12, 2025 ClearPoint Neuro Announces Investment of up to $110 Million by Oberland Capital with $33.5 Million Funded at Closing SOLANA BEACH, CALIFORNIA / (ACCESS Newswire) / May 12, 2025 / ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it has ent

Form of Note Purchase Agreement

Exhibit 10.2 NOTE PURCHASE AGREEMENT dated as of May 12, 2025 among CLEARPOINT NEURO, INC. as Issuer, THE OTHER OBLIGORS PARTY HERETO, THE PURCHASERS PARTY HERETO, and CALW SA LLC as Purchaser Agent Table of Contents Page Article I ACCOUNTING AND OTHER TERMS 1 Article II Notes; Terms of Payment; Revenue Participation 2 Section 2.1 Purchase and Sale of Notes. 2 Section 2.2 Payments of Repayment Amo

ClearPoint Neuro, Inc.

Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-275476 PROSPECTUS SUPPLEMENT (To Prospectus dated November 9, 2023) 275,808 Shares of Common Stock ClearPoint Neuro, Inc. We are offering 275,808 shares (the “Shares”) of our common stock, par value $0.01 per share (“Common Stock”), in a registered direct offering to certain investors (the “Investors”) in a privately negotiate

Form of Stock Purchase Agreement

Exhibit 10.1 STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (this “Agreement”), is made and entered into as of May 12, 2025 (the “Execution Date”), by and between (i) TPC INVESTMENTS III LP, a Delaware limited partnership (the “Investor”) and (ii) CLEARPOINT NEURO, INC., a Delaware corporation (the “Company”). The Investor and the Company are referred to herein, collectively, as the “Parti

FORM 8-K Item 1.01 Entry into a Material Definitive Agreement. Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 CLEARPOINT NEURO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34822 58-2394628 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY.Nasdaq: CLPTFebruary 2025

WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY. Nasdaq: CLPT February 2025 DISCLAIMER This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company’s expectation for revenues, gross margin, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, the future market of its products

Subsidiaries of ClearPoint Neuro, Inc.

EXHIBIT 21 List of Subsidiaries Name of Subsidiary Jurisdiction of Formation ClearPoint Neuro (Canada) Inc. Canada (New Brunswick) ClearPoint Neuro UK Ltd United Kingdom ClearPoint Neuro Germany GmbH. Germany ClearPoint Neuro Italy, S.r.l. Italy

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-34822 CLEAR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 ClearPoint Neuro, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34822 58-2394628 (State or Other Jurisdiction of Incorporation) (Commissio

ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results Achieved Record Revenue for 2024 and Growth of 31%; Reduced 2024 Operational Cash Burn by 35%

Exhibit 99.1 ClearPoint Neuro Reports Fourth Quarter and Full Year 2024 Results Achieved Record Revenue for 2024 and Growth of 31%; Reduced 2024 Operational Cash Burn by 35% SOLANA BEACH, CA, February 26, 2025 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financia

CLPT / ClearPoint Neuro, Inc. / Bigger Capital, LLC Passive Investment

SC 13G/A 1 sc13ga410022clpt11082024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 ClearPoint Neuro, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 CLEARPOINT NEURO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission

Up to $50,000,000 Common Stock

TABLE OF CONTENTS  Filed pursuant to Rule 424(b)(5)  Registration No. 333-275476 PROSPECTUS SUPPLEMENT (to Prospectus dated November 20, 2023) Up to $50,000,000 Common Stock ClearPoint Neuro, Inc. has entered into an At-The-Market Equity Offering Sales Agreement (the “Sales Agreement”) with Stifel, Nicolaus & Company, Incorporated (the “Agent”), relating to our common stock offered by this prospec

© 2 0 2 4 C L E A R P O I N T N E U R O 1 © 2 0 2 4 C L E A R P O I N T N E U R O 2 This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company’s expectation for revenue

© 2 0 2 4 C L E A R P O I N T N E U R O 1 © 2 0 2 4 C L E A R P O I N T N E U R O 2 This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company’s expectation for revenues, gross margin, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, the future market of its products and services, and other performance and results.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 CLEARPOINT NEURO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-34822 ClearP

ClearPoint Neuro Reports Third Quarter 2024 Results Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million

Exhibit 99.1 ClearPoint Neuro Reports Third Quarter 2024 Results Achieved Record Revenue and Growth of 41%; Operational Cash Burn Reduced to $1.2 Million SOLANA BEACH, CA, November 7, 2024 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its thi

At-The-Market Equity Offering Sales Agreement, dated November 7, 2024, by and between the Company and Stifel, Nicolaus & Company, Incorporated.

Exhibit 1.1 CLEARPOINT NEURO, INC. Common Stock ($0.01 par value per share) AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT November 7, 2024 STIFEL, NICOLAUS & COMPANY, INCORPORATED One South Street, 15th Floor Baltimore, Maryland 21202 Ladies and Gentlemen: ClearPoint Neuro, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell

CLPT / ClearPoint Neuro, Inc. / Ptc Therapeutics, Inc. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* ClearPoint Neuro, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 55347P209 (CUSIP Number) Mark E. Boulding Executive Vice President and Chief Legal Officer PTC Therapeutics, Inc. 500 Warren Corporate Center D

ClearPoint Neuro Announces Early Repayment of $10 Million Note

Exhibit 99.1 ClearPoint Neuro Announces Early Repayment of $10 Million Note SOLANA BEACH, CA, August 26, 2024 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that on August 23, 2024, it provided for the full early repayment of the principal amount and interest on a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2024 CLEARPOINT NEURO,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2024 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-34822 ClearPoint

ClearPoint Neuro Reports Second Quarter 2024 Results Second Quarter Revenue Growth +32%; Record Revenue Achieved

Exhibit 99.1 ClearPoint Neuro Reports Second Quarter 2024 Results Second Quarter Revenue Growth +32%; Record Revenue Achieved SOLANA BEACH, CA, August 7, 2024 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its second quarter ended June 30, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 CLEARPOINT NEURO,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission F

© 2 0 24 C LE A R P OI N T NE UR O 1 © 2 0 24 C LE A R P OI N T NE UR O 2 This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company’s expectation for revenues, gross m

© 2 0 24 C LE A R P OI N T NE UR O 1 © 2 0 24 C LE A R P OI N T NE UR O 2 This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company’s expectation for revenues, gross margin, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, the future market of its products and services, and other performance and results.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ClearPoint Neuro, Inc.

shar As filed with the Securities and Exchange Commission on May 16, 2024

shar As filed with the Securities and Exchange Commission on May 16, 2024 Registration Statement No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 CLEARPOINT NEURO, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission File

© 2 0 2 4 C L E A R P O I N T N E U R O 1 © 2 0 2 4 C L E A R P O I N T N E U R O 2 This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company’s expectation for revenue

© 2 0 2 4 C L E A R P O I N T N E U R O 1 © 2 0 2 4 C L E A R P O I N T N E U R O 2 This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company’s expectation for revenues, gross margin, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, the future market of its products and services, and other performance and results.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-34822 ClearPoint

ClearPoint Neuro Reports First Quarter 2024 Results First Quarter Revenue Growth +41%; Record Revenue Achieved

Exhibit 99.1 ClearPoint Neuro Reports First Quarter 2024 Results First Quarter Revenue Growth +41%; Record Revenue Achieved SOLANA BEACH, CA, May 7, 2024 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2024. Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Insider Trading Compliance Policy, adopted on July 17, 2023

ClearPoint Neuro, Inc. Insider Trading Compliance Policy Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information and providing material nonpublic information to others so that they can trade. Violating such laws can undermine investor trust, harm ClearPoint Neuro, Inc.’s reputation, and result in your dismissal from ClearPoint Ne

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-34822 CLEAR

ClearPoint Neuro, Inc. Compensation Recoupment Policy, adopted on October 3, 2023

ClearPoint Neuro, Inc. Compensation Recoupment Policy 1. Purpose. The purpose of this Compensation Recoupment Policy of the Company (as amended from time to time, the “Policy”), dated as of October 3, 2023 (the “Adoption Date”) is to describe the circumstances in which current and former Executive Officers will be required to repay or return Erroneously Awarded Compensation to members of the Compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 CLEARPOINT NEURO,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission F

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results Release Includes Commentary on Early 2024 Progress

Exhibit 99.1 ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results Release Includes Commentary on Early 2024 Progress SOLANA BEACH, CA, March 12, 2024 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its fourth quarter and full-year

escription of Securities

EXHIBIT 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ClearPoint Neuro, Inc. (“ClearPoint,” “we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, par value $0.01 per share (“Common Stock”). Authorized Shares of

© 2 0 2 4 C L E A R P O I N T N E U R O 1 © 2 0 2 4 C L E A R P O I N T N E U R O 2 This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company’s expectation for revenue

© 2 0 2 4 C L E A R P O I N T N E U R O 1 © 2 0 2 4 C L E A R P O I N T N E U R O 2 This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company’s expectation for revenues, gross margin, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, the future market of its products and services, and other performance and results.

Subsidiaries of ClearPoint Neuro, Inc.

EXHIBIT 21 List of Subsidiaries Name of Subsidiary Jurisdiction of Formation ClearPoint Neuro (Canada) Inc. Canada (New Brunswick) ClearPoint Neuro UK Ltd United Kingdom ClearPoint Neuro Germany GmbH. Germany ClearPoint Neuro Italy, S.r.l. Italy

2,307,694 Shares Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(2)  Registration No. 333-275476 PROSPECTUS SUPPLEMENT (To Prospectus dated November 20, 2023) 2,307,694 Shares Common Stock We are offering 2,307,694 shares of our common stock, par value $0.01 per share (“common stock”), at a purchase price of $6.50 per share in this offering pursuant to this prospectus supplement and the accompanying prospectus. O

Underwriting Agreement, dated as of February 28, 2024, by and between ClearPoint Neuro, Inc. and Lake Street Capital Markets, LLC, as representative of the several underwriters named in Schedule A thereto.

Exhibit 1.1 2,307,694 Shares CLEARPOINT NEURO, INC. COMMON STOCK UNDERWRITING AGREEMENT February 28, 2024 Lake Street Capital Markets, LLC As Representative of the several Underwriters 920 Second Avenue South, Suite 700 Minneapolis, Minnesota 55402 Ladies and Gentlemen: 1. Introductory. ClearPoint Neuro, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this

EX-FILING FEES

Exhibit 107 The prospectus to which this Exhibit 107 is attached is a final prospectus for the related offering. The maximum aggregate offering price for such offering is $17,250,012.

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2024 (February 28, 2024) CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorpora

Subject to completion, dated February 28, 2024

TABLE OF CONTENTS This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but the information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed.

MRIC / MRI Interventions Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SC 13G 1 tv0623-clearpointneuroinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: ClearPoint Neuro Inc Title of Class of Securities: Common Stock CUSIP Number: 18507C103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant t

MRIC / MRI Interventions Inc / Bigger Capital, LLC Passive Investment

SC 13G/A 1 sc13ga310022clpt02062024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 ClearPoint Neuro, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 CLEARPOINT NEURO,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission

TM © 2 0 2 4 C L E A R P O I N T N E U R O 2 This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company’s expectation for revenues, gross margin, the adequacy of cash a

clptinvestordeckjpm2024 TM © 2 0 2 4 C L E A R P O I N T N E U R O 2 This presentation and discussion contain forward-looking statements within the context of the federal securities laws, including the Company’s expectation for revenues, gross margin, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, the future market of its products and services, and other performance and results.

ClearPoint Neuro Reports Fourth Quarter and Full Year 2023 Preliminary Revenue Results and Guidance for Full Year 2024 Revenue

Exhibit 99.1 ClearPoint Neuro Reports Fourth Quarter and Full Year 2023 Preliminary Revenue Results and Guidance for Full Year 2024 Revenue SOLANA BEACH, CA, January 8, 2024 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced preliminary, unaudited financial results for its fourth quarte

CLEARPOINT NEURO, INC. 120 S. Sierra Avenue, Suite 100 Solana Beach, California 92075

CLEARPOINT NEURO, INC. 120 S. Sierra Avenue, Suite 100 Solana Beach, California 92075 November 17, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jessica Ansart Re: ClearPoint Neuro, Inc. Registration Statement on Form S-3 (File No. 333-275476) Request for Acceleration Ladies and Gentlemen: Pursuant to Rul

Filing Fee Table (filed herewith)

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form type) CLEARPOINT NEURO, INC.

Form of Indenture (filed herewith)

Exhibit 4.5 CLEARPOINT NEURO, INC. and , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS Article I. DEFINITIONS AND INCORPORATION BY REFERENCE 2 1.1. DEFINITIONS. 2 1.2. OTHER DEFINITIONS. 5 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT. 6 1.4. RULES OF CONSTRUCTION. 6 Article II. THE SECURITIES 6 2.1. ISSUABLE IN SERIES. 6 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES. 7 2.3.

TM © 2 0 2 3 C L E A R P O I N T N E U R O 2 Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future e

TM © 2 0 2 3 C L E A R P O I N T N E U R O 2 Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-34822 ClearP

ClearPoint Neuro Reports Third Quarter 2023 Results Biologics & Drug Delivery Growing 55%; Q3 Operational Cash Burn of $1.8M

Exhibit 99.1 ClearPoint Neuro Reports Third Quarter 2023 Results Biologics & Drug Delivery Growing 55%; Q3 Operational Cash Burn of $1.8M SOLANA BEACH, CA, November 9, 2023 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 202

As filed with the Securities and Exchange Commission on November 9, 2023

As filed with the Securities and Exchange Commission on November 9, 2023 Registration No.

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission

ClearPoint Neuro Reports Second Quarter 2023 Results Biologics & Drug Delivery growing +40%; Company Reaffirms 2023 Revenue Forecast

Exhibit 99.1 ClearPoint Neuro Reports Second Quarter 2023 Results Biologics & Drug Delivery growing +40%; Company Reaffirms 2023 Revenue Forecast SOLANA BEACH, CA, August 8, 2023 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its second quarter ended June 30, 2

TM © 2 0 2 3 C L E A R P O I N T N E U R O 2 Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future e

clptinvestordeckaugustx TM © 2 0 2 3 C L E A R P O I N T N E U R O 2 Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-34822 ClearPoint

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission F

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission F

Third Omnibus Amendment to the Securities Purchase Agreement and Senior Secured Convertible Notes, dated July 31, 2023, by and among ClearPoint Neuro, Inc., PTC Therapeutics, Inc., and Petrichor Opportunities Fund I LP

THIRD OMNIBUS AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT AND SENIOR SECURED CONVERTIBLE NOTES This THIRD OMNIBUS AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT AND SENIOR SECURED CONVERTIBLE NOTES (this “Third Amendment”) is dated as of July 31, 2023 and is made in reference to that certain Securities Purchase Agreement, dated as of January 11, 2020 (as heretofore has been, and as hereafter may be, amended, restated or otherwise modified, the “Purchase Agreement”), by and among ClearPoint Neuro, Inc.

MRIC / MRI Interventions Inc / Ptc Therapeutics, Inc. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* ClearPoint Neuro, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 55347P209 (CUSIP Number) Mark E. Boulding Executive Vice President and Chief Legal Officer PTC Therapeutics, Inc. 100 Corporate Court South Pla

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of ClearPoint Neuro, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, filed with the SEC on May 25, 2023).

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CLEARPOINT NEURO, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware CLEARPOINT NEURO, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: 1.Section A of Article IV of th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 CLEARPOINT NEURO, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 CLEARPOINT NEURO, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2023 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission Fil

ClearPoint Neuro, Inc. Non-Employee Director Compensation Plan, as amended and restated by the Board of Directors on May 22, 2023

Exhibit 10.1 CLEARPOINT NEURO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PLAN This Non-Employee Director Compensation Plan (this “Plan”) sets forth the compensation for non-employee members of the Board of Directors (the “Board”) of ClearPoint Neuro, Inc. (the “Company”). This Plan applies only to non-employee members of the Board and is not applicable to employee members of the Board. This Plan wil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 CLEARPOINT NEURO, IN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-34822 ClearPoint

ClearPoint Neuro Reports First Quarter 2023 Results Biologics & Drug Delivery growing +24%; Company Reaffirms 2023 Revenue Forecast

Exhibit 99.1 ClearPoint Neuro Reports First Quarter 2023 Results Biologics & Drug Delivery growing +24%; Company Reaffirms 2023 Revenue Forecast SOLANA BEACH, CA, May 11, 2023 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its first quarter ended March 31, 2023

Employment Agreement, dated May 31, 2022, by and between the Company and Jeremy Stigall

EMPLOYMENT AGREEMENT THIS AGREEMENT (this “Agreement”) is entered into as of this 16th day of May, 2022 (the “Effective Date”), by and between CLEARPOINT NEURO, INC.

TM © 2 0 2 3 C L E A R P O I N T N E U R O 2 Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future e

clptinvestordeckmayx202 TM © 2 0 2 3 C L E A R P O I N T N E U R O 2 Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws.

Amendment No. 1 to Employment Agreement, dated March 3, 2023 by and between the Company and Jeremy Stigall, amending the Employment Agreement dated May 31, 2022

clpt-xamendmentxnox1xto AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 (this “Amendment”) to the Employment Agreement (the “Agreement”), dated as of May 16, 2022, by and between ClearPoint Neuro, Inc., a Delaware corporation (the “Company”), and Jeremy L. Stigall (“Executive”), is dated as of March 3, 2023 (the “Effective Date”), and is by and between the Company and Executive. Capit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Amendment No. 1 to Employment Agreement, dated March 3, 2023 by and between the Company and Joseph M. Burnett, amending the Employment Agreement dated October 6, 2017

Exhibit 10.1 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 (this “Amendment”) to the Employment Agreement (the “Agreement”), dated as of October 6, 2017, by and between ClearPoint Neuro, Inc., a Delaware corporation (the “Company”), and Joseph M. Burnett (“Executive”), is dated as of March 3, 2023 (the “Effective Date”), and is by and between the Company and Executive. Capitalized t

Amendment No. 1 to Employment Agreement, dated March 3, 2023 by and between the Company and Danilo D’Alessandro, amending the Employment Agreement dated September 14, 2020

Exhibit 10.2 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 (this “Amendment”) to the Employment Agreement (the “Agreement”), dated as of September 14, 2020, by and between ClearPoint Neuro, Inc., a Delaware corporation (the “Company”), and Danilo D’Alessandro (“Executive”), is dated as of March 3, 2023 (the “Effective Date”), and is by and between the Company and Executive. Capitali

Amendment No. 1 to Employment Agreement, dated March 3, 2023 by and between the Company and Mazin Sabra, amending the Employment Agreement dated September 20, 2022

Exhibit 10.3 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT THIS AMENDMENT NO. 1 (this “Amendment”) to the Employment Agreement (the “Agreement”), dated as of September 20, 2022, by and between ClearPoint Neuro, Inc., a Delaware corporation (the “Company”), and Mazin Sabra (“Executive”), is dated as of March 3, 2023 (the “Effective Date”), and is by and between the Company and Executive. Capitalized term

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023 CLEARPOINT NEURO, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission Fi

Subsidiaries of ClearPoint Neuro, Inc.

EX-21 3 clpt-20221231x10kex21.htm EX-21 EXHIBIT 21 List of Subsidiaries Name of Subsidiary Jurisdiction of Formation ClearPoint Neuro (Canada) Inc. Canada (New Brunswick) ClearPoint Neuro UK Ltd United Kingdom

ClearPoint Neuro, Inc. 2013 Incentive Compensation Plan Form of Restricted Share Unit Award Agreement

Exhibit 10.38 RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE CLEARPOINT NEURO, INC. FOURTH AMENDED AND RESTATED 2013 INCENTIVE COMPENSATION PLAN Name of Grantee: No. of Restricted Stock Units: Grant Date: Pursuant to the ClearPoint Neuro, Inc. Fourth Amended and Restated 2013 Incentive Compensation Plan as amended through the date hereof (the “Plan”), ClearPoint Neuro, Inc. (the “Company”) hereby

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2022 Results Company Reports Record Revenues

Exhibit 99.1 ClearPoint Neuro Reports Fourth Quarter and Full-Year 2022 Results Company Reports Record Revenues SOLANA BEACH, CA, March 1, 2023 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its fourth quarter and full-year ended December 31, 2022. 2022 Full Ye

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 CLEARPOINT NEURO, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2023 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-34822 CLEAR

MRIC / MRI Interventions Inc / BIGGER CAPITAL FUND L P Passive Investment

SC 13G/A 1 sc13ga210022clpt02092023.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 ClearPoint Neuro, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission

ClearPoint Neuro Reports Fourth Quarter and Full Year 2022 Preliminary Revenue Results and Guidance for Full Year 2023 Revenue

Exhibit 99.1 ClearPoint Neuro Reports Fourth Quarter and Full Year 2022 Preliminary Revenue Results and Guidance for Full Year 2023 Revenue SOLANA BEACH, CA, January 11, 2023 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced preliminary, unaudited financial results for its fourth quart

TM © 2 0 2 3 C L E A R P O I N T N E U R O 2 Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future e

TM © 2 0 2 3 C L E A R P O I N T N E U R O 2 Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws.

Fourth Amended and Restated Bylaws of ClearPoint Neuro, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the SEC on December 14, 2022).

EX-3.1 2 finalproposed-clptbylaws.htm EX-3.1 EXHIBIT 3.1 FOURTH AMENDED AND RESTATED BYLAWS OF CLEARPOINT NEURO, INC. (the “Corporation”) ARTICLE I OFFICES 1.1Registered Office. The address of the registered office of this Corporation in the State of Delaware is 1209 Orange Street, City of Wilmington, County of New Castle, Zip Code 19801, and the name of the registered agent of this Corporation in

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commissio

ClearPoint Neuro Reports Third Quarter 2022 Results Company Reaffirms 2022 Revenue Forecast

Exhibit 99.1 ClearPoint Neuro Reports Third Quarter 2022 Results Company Reaffirms 2022 Revenue Forecast SOLANA BEACH, CA, November 8, 2022 ? ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the ?Company?), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2022. Third Quarter Highlights ?Repo

TM © 2 0 2 2 C L E A R P O I N T N E U R O 2 Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future e

TM ? 2 0 2 2 C L E A R P O I N T N E U R O 2 Statements herein concerning the Company?s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws.

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-34822 ClearP

Standard Industrial/Commercial Single-Tenant Lease - Net, dated November 4, 2022 between ClearPoint Neuro, Inc. and the Hedda Marosi Living Trust and the Stella Feder Trust

INITIALS INITIALS ? 2019 AIR CRE. All Rights Reserved. Last Edited: 11/4/2022 5:47AM STN-27.30, Revised 10-22-2020 Page 1of 14 1. Basic Provisions ("Basic Provisions"). 1.1 Par es. This Lease ("Lease"), dated for reference purposes only November 4, 2022 , is made by and between Hedda Marosi Living Trust and Stella Feder Trust (collectively, "Lessor") and ClearPoint Neuro, Inc., a Delaware corporat

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2022 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission

Employment Agreement, dated September 20, 2022, by and between the Company and Mazin Sabra

EMPLOYMENT AGREEMENT THIS AGREEMENT (this ?Agreement?) is entered into as of this 20th day of September, 2022 (the ?Effective Date?), by and between CLEARPOINT NEURO, INC.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commissi

ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer

Exhibit 99.1 ClearPoint Neuro Announces Appointment of Mazin Sabra as Chief Operating Officer SOLANA BEACH, CA, September 20, 2022 ? ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the ?Company?), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mazin Sabra will join the Company effective October 10th as Chief Operating Officer. Mr. Sabra will

ClearPoint Neuro, Inc. Fourth Amended and Restated 2013 Incentive Compensation Plan Form of Restricted Stock Unit Award Agreement

Exhibit 10.3 RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE CLEARPOINT NEURO, INC. FOURTH AMENDED AND RESTATED 2013 INCENTIVE COMPENSATION PLAN Name of Grantee: No. of Restricted Stock Units: Grant Date: Pursuant to the ClearPoint Neuro, Inc. Fourth Amended and Restated 2013 Incentive Compensation Plan as amended through the date hereof (the ?Plan?), ClearPoint Neuro, Inc. (the ?Company?) hereby

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-34822 ClearPoint

ClearPoint Neuro Reports Second Quarter 2022 Results Record Quarterly Revenue Achieved; Company Reaffirms 2022 Revenue Forecast

EX-99.1 2 clpt-20220809xexx991.htm EX-99.1 Exhibit 99.1 ClearPoint Neuro Reports Second Quarter 2022 Results Record Quarterly Revenue Achieved; Company Reaffirms 2022 Revenue Forecast SOLANA BEACH, CA, August 9, 2022 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results f

TM © 2 0 2 2 C L E A R P O I N T N E U R O 2 Statements herein concerning the Company’s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future e

TM ? 2 0 2 2 C L E A R P O I N T N E U R O 2 Statements herein concerning the Company?s plans, growth and strategies may include forward-looking statements within the context of the federal securities laws.

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission F

Certificate of Correction of Certificate of Amendment of Amended and Restated Certificate of Incorporation of ClearPoint Neuro, Inc.

CERTIFICATE OF CORRECTION OF CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CLEARPOINT NEURO, INC.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission Fil

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) ClearPoint Neuro, Inc.

shar As filed with the Securities and Exchange Commission on June 1, 2022

shar As filed with the Securities and Exchange Commission on June 1, 2022 Registration Statement No.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 (May 24, 2022) CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation)

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of ClearPoint Neuro, Inc.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CLEARPOINT NEURO, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware CLEARPOINT NEURO, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), does hereby certify as follows: 1. Section A of Article IV of t

ClearPoint Neuro, Inc. Non-Employee Director Compensation Plan, as amended and restated by the Board of Directors on May 21, 2022.

Exhibit 10.1 CLEARPOINT NEURO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PLAN This Non-Employee Director Compensation Plan (this ?Plan?) sets forth the compensation for non-employee members of the Board of Directors (the ?Board?) of ClearPoint Neuro, Inc. (the ?Company?). This Plan applies only to non-employee members of the Board and is not applicable to employee members of the Board. This Plan wil

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 (May 21, 2022) ClearPoint Neuro, Inc. (Exact name of registrant as specified in its charter) delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation)

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission Fil

ClearPoint Neuro Reports First Quarter 2022 Results

EX-99 2 ex99-1.htm CLEARPOINT NEURO REPORTS FIRST QUARTER 2022 RESULTS Exhibit 99.1 ClearPoint Neuro Reports First Quarter 2022 Results SOLANA BEACH, CA, May 11, 2022 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its first quarter ended March 31, 2022. First Q

Investor Presentation dated May 2022

EX-99 3 ex99-2.htm INVESTOR PRESENTATION Exhibit 99.2

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-34822 ClearPoint

Appendix A to ClearPoint Neuro, Inc.'s Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 14, 2022

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-34822 CLEAR

Subsidiaries of ClearPoint Neuro, Inc.

EXHIBIT 21 List of Subsidiaries Name of Subsidiary Jurisdiction of Formation ClearPoint Neuro (Canada) Inc. Canada (New Brunswick) ClearPoint Neuro UK Ltd United Kingdom

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2021 Results Company Reports Record Revenues

Exhibit 99.1 ClearPoint Neuro Reports Fourth Quarter and Full-Year 2021 Results Company Reports Record Revenues SOLANA BEACH, CA, March 1, 2022 ? ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the ?Company?), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its fourth quarter and full-year ended December 31, 2021. 2021 Full Ye

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission Fi

ClearPoint Neuro Reports Fourth Quarter and Full Year 2021 Preliminary Revenue Results and Guidance for Full Year 2022 Revenue Company to Hold Earnings Call on March 1, 2022

Exhibit 99.1 ClearPoint Neuro Reports Fourth Quarter and Full Year 2021 Preliminary Revenue Results and Guidance for Full Year 2022 Revenue Company to Hold Earnings Call on March 1, 2022 SOLANA BEACH, CA, February 15, 2022 ? ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the ?Company?), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced preliminary,

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commissio

Investor Presentation dated February 2022

Exhibit 99.2

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2022 (February 9, 2022) CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) delaware 001-34822 58-2394628 (State or other jurisdiction of incorp

Confidential Resignation Agreement, dated as of February 14, 2022, by and between the Company and Peter G. Piferi

Exhibit 10.1 CONFIDENTIAL RESIGNATION AGREEMENT This confidential resignation agreement (the ?Agreement?) is executed by and between Peter G. Piferi (?Employee?) and ClearPoint Neuro, Inc., a Delaware corporation (?Employer? or ?Company?) and each of its clients, affiliates, parent companies, divisions, subsidiaries, predecessors, and all related companies or entities and all of its/their present

Independent Consultant Agreement, dated as of dated as of February 14, 2022, by and between the Company and Peter G. Piferi

Exhibit 10.2 INDEPENDENT CONTRACTOR CONSULTING AGREEMENT THIS INDEPENDENT CONTRACTOR CONSULTING AGREEMENT (the ?Agreement?) is entered into on the 14th day of February, 2022 and will be effective on the 21st day of February, 2022 (the ?Start Date?), by and between ClearPoint Neuro, Inc., a Delaware corporation (?CLPT?), and Peter Piferi (?Consultant?). W I T N E S S E T H: WHEREAS, CLPT is a medic

MRIC / MRI Interventions Inc / BIGGER CAPITAL FUND L P Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 ClearPoint Neuro, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 55347P209 (CUSIP Number) De

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commissio

Third Amended and Restated Bylaws of ClearPoint Neuro, Inc.

Exhibit 3.1 THIRD AMENDED AND RESTATED BYLAWS OF ClearPoint Neuro, INC. (the ?Corporation?) ARTICLE I OFFICES 1.1 Registered Office. The address of the registered office of this Corporation in the State of Delaware is 1209 Orange Street, City of Wilmington, County of New Castle, Zip Code 19801, and the name of the registered agent of this Corporation in the State of Delaware at such address is The

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-34822 ClearP

Investor Presentation dated November 2021

Exhibit 99.2

ClearPoint Neuro Reports Third Quarter 2021 Results Record Revenue Achieved; Company Reaffirms 2021 Revenue Forecast

Exhibit 99.1 ClearPoint Neuro Reports Third Quarter 2021 Results Record Revenue Achieved; Company Reaffirms 2021 Revenue Forecast SOLANA BEACH, CA, November 9, 2021 ? ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the ?Company?), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2021. Third

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission

Internationally Renowned Neurosurgeon and Accomplished Researcher Dr. Linda M. Liau Joins ClearPoint Neuro Board of Directors

Exhibit 99.1 For Immediate Release Internationally Renowned Neurosurgeon and Accomplished Researcher Dr. Linda M. Liau Joins ClearPoint Neuro Board of Directors SOLANA BEACH, CA, November 2, 2021 ? ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the ?Company?), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Linda M. Liau, MD, PhD, MBA,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-34822 ClearPoint

Investor Presentation dated August 2021

EX-99.2 3 ex99-2.htm Exhibit 99.2

ClearPoint Neuro Reports Second Quarter 2021 Results Record Case Volume Supported Clinically During the Quarter

Exhibit 99.1 ClearPoint Neuro Reports Second Quarter 2021 Results Record Case Volume Supported Clinically During the Quarter SOLANA BEACH, CA, August 10, 2021 ? ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the ?Company?), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its second quarter ended June 30, 2021. Second Quarter

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 eps9721.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2021 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporati

ClearPoint Neuro, Inc. Announces Appointment of Lynnette C. Fallon to Board of Directors

Exhibit 99.1 For Immediate Release ClearPoint Neuro, Inc. Announces Appointment of Lynnette C. Fallon to Board of Directors SOLANA BEACH, CA, July 15, 2021 ? ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the ?Company?), a global therapy-enabling platform company providing navigation and delivery to the brain, is pleased to announce that Lynnette C. Fallon has been appointed to the Company?s Board of Dire

ClearPoint Neuro, Inc. Executive Officer and Director Stock Ownership Guidelines As adopted on June 25, 2021

Exhibit 99.1 ClearPoint Neuro, Inc. Executive Officer and Director Stock Ownership Guidelines As adopted on June 25, 2021 Statement of Policy The Board of Directors (the ?Board?) of ClearPoint Neuro, Inc. (?CLPT? or the ?Company?) has adopted these stock ownership guidelines to further align the interest of the Company?s executive officers and directors with the interests of its stockholders and t

Financial Statements and Exhibits, Other Events

8-K 1 eps9675.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2021 (June 25, 2021) CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdictio

ClearPoint Neuro, Inc. Non-Employee Director Compensation Plan, as amended and restated by the Board of Directors on June 25, 2021.

Exhibit 10.1 CLEARPOINT NEURO, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PLAN This Non-Employee Director Compensation Plan (this ?Plan?) sets forth the compensation for non-employee members of the Board of Directors (the ?Board?) of ClearPoint Neuro, Inc. (the ?Company?). This Plan applies only to non-employee members of the Board and is not applicable to employee members of the Board. This Plan wil

Exhibit 10.2

Exhibit 10.2 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this ?Agreement?) is made as of the day of , 20 by and between ClearPoint Neuro, Inc., a Delaware corporation (the ?Company?), and (the ?Indemnitee?). WHEREAS, the Board of Directors has determined that the increasing difficulty in attracting and retaining qualified persons as directors and officers is detrimental to the best i

Joint Filing Agreement

EX-99.1 2 ex991to13g1002200206092021.htm Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated June 9, 2021 with respect to the shares of Common Stock of ClearPoint Neuro, Inc., and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the

MRIC / MRI Interventions Inc / BIGGER CAPITAL FUND L P Passive Investment

SC 13G 1 sc13g1002200206092021.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 ClearPoint Neuro, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Secur

As filed with the Securities and Exchange Commission on June 4, 2021

As filed with the Securities and Exchange Commission on June 4, 2021 Registration No.

2021 Employee Stock Purchase Plan

EX-99 4 ex99-1.htm 2021 EMPLOYEE STOCK PURCHASE PLAN Exhibit 99.1 CLEARPOINT NEURO, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN 1. Establishment of Plan. ClearPoint Neuro, Inc. a Delaware corporation (the “Company”), proposes to grant options to purchase shares of Common Stock to eligible employees of the Company and its Participating Corporations pursuant to this Plan. The Company intends this Plan to

Regulation FD Disclosure, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2021 (June 3, 2021) CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incorporation)

Regulation FD Disclosure, Financial Statements and Exhibits

8-K 1 eps9659.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2021 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorporatio

Investor Presentation dated May 2021

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Investor Presentation dated May 2021

EX-99.1 2 ex99-1.htm Exhibit 99.1

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2021 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission Fil

Quarterly Report -

10-Q 1 eps9615.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number:

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission Fil

ClearPoint Neuro Reports Record Revenue in First Quarter 2021 Results, Announces FDA Clearance of the SmartFrame ‘Array’

Exhibit 99.1 ClearPoint Neuro Reports Record Revenue in First Quarter 2021 Results, Announces FDA Clearance of the SmartFrame ?Array? SOLANA BEACH, CA, May 11, 2021 ? ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the ?Company?), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its first quarter ended March 31, 2021. First Qua

ClearPoint Neuro, Inc. 2021 Employee Stock Purchase Plan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

ClearPoint Neuro, Inc. Announces Retirement of Director John N. Spencer, Jr.

Exhibit 99.1 For Immediate Release ClearPoint Neuro, Inc. Announces Retirement of Director John N. Spencer, Jr. SOLANA BEACH, CA, April 13, 2021 ? ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the ?Company?), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today the upcoming retirement of John N. Spencer, Jr. from its Board of Directors. Mr. Spencer, w

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

8-K 1 eps9581.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2021 (April 12, 2021) CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdict

Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-34822 CLEARPOINT NEURO, INC.

Subsidiaries of MRI Interventions, Inc.

EXHIBIT 21 List of Subsidiaries Name of Subsidiary Jurisdiction of Formation ClearPoint Neuro (Canada) Inc. Canada (New Brunswick) ClearPoint Neuro UK Ltd United Kingdom

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2020 Results Company Reports Record Revenues

Exhibit 99.1 ClearPoint Neuro Reports Fourth Quarter and Full-Year 2020 Results Company Reports Record Revenues IRVINE, CA, March 4, 2021 ? ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the ?Company?), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its fourth quarter and full-year ended December 31, 2020. 2020 Full Year and

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2021 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission Fi

Under the Securities Exchange Act of 1934 (Amendment No. 2)* ClearPoint Neuro, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) (CUSIP Number) Mark E. Boulding Executive Vice President and Chief Legal Offic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* ClearPoint Neuro, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 55347P209 (CUSIP Number) Mark E. Boulding Executive Vice President and Chief Legal Officer PTC Therapeutics, Inc. 100 Corporate Court South Pla

1,850,140 Shares Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-252346 Prospectus Supplement (To Prospectus dated January 29, 2021) 1,850,140 Shares Common Stock We are offering 1,850,140 shares of our common stock, par value $0.01 per share (?common stock?), at a purchase price of $23.50 per share in this offering pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is l

Underwriting Agreement, dated as of February 18, 2021, by and between ClearPoint Neuro, Inc. and B. Riley Securities, Inc., as representative of the several underwriters named in Schedule A thereto.

EX-1.1 2 ex1-1.htm Exhibit 1.1 1,850,140 Shares CLEARPOINT NEURO, INC. COMMON STOCK UNDERWRITING AGREEMENT February 18, 2021 B. Riley Securities, Inc. As Representative of the several Underwriters c/o B. Riley Securities, Inc. 11100 Santa Monica Blvd., Suite 800 Los Angeles, CA 90025 Ladies and Gentlemen: 1. Introductory. ClearPoint Neuro, Inc., a Delaware corporation (the “Company”), proposes to

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2021 (February 18, 2021) CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) Delaware 001-34822 58-2394628 (State or other jurisdiction of incor

Investor Presentation dated February 19, 2021.

Exhibit 99.1

Subject to completion, dated February 18, 2021

Filed Pursuant to Rule 424(b)(5) Registration No. 333-252346 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but the information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer t

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 4)* Clear

SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 4)* ClearPoint Neuro, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 55347P209 (CUSIP Number) December 31, 2020 (Date of Event Whic

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2021 (February 4, 2021) ClearPoint Neuro, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorpo

ClearPoint Neuro, Inc. Announces Appointment of R. John Fletcher as Chairman of the Board of Directors

Exhibit 99.1 For Immediate Release ClearPoint Neuro, Inc. Announces Appointment of R. John Fletcher as Chairman of the Board of Directors IRVINE, CA, February 5, 2021 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today announced that R. John Fletcher has been appointed Chairman of the Company’s Board of Directors. The prior Chairman, Kimble L. Jenkins, retired from the Chairman role, whi

-

CORRESP 1 filename1.htm CLEARPOINT NEURO, INC. 5 Musick Irvine, California 92618 January 27, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Jason Drory Re: ClearPoint Neuro, Inc. Registration Statement on Form S-3 (File No. 333-252346) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulg

-

As filed with the Securities and Exchange Commission on January 22, 2021 Registration No.

Form of Indenture

EX-4.5 2 ex4-5.htm Exhibit 4.5 CLEARPOINT NEURO, INC. and , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS Article I. DEFINITIONS AND INCORPORATION BY REFERENCE 2 1.1. DEFINITIONS. 2 1.2. OTHER DEFINITIONS. 5 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT. 6 1.4. RULES OF CONSTRUCTION. 6 Article II. THE SECURITIES 7 2.1. ISSUABLE IN SERIES. 7 2.2. ESTABLISHMENT OF TERMS OF SERIES OF

ClearPoint Neuro, Inc. Reports Record Revenue in Preliminary Fourth Quarter 2020 Results

EX-99 2 ex99-1.htm PRESS RELEASE Exhibit 99.1 For Immediate Release ClearPoint Neuro, Inc. Reports Record Revenue in Preliminary Fourth Quarter 2020 Results IRVINE, CA, January 12, 2021 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today reported preliminary unaudited revenue results for the quart

Results of Operations and Financial Condition -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2020 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commissio

Second Omnibus Amendment to the Securities Purchase Agreement and Senior Secured Convertible Notes, dated December 29, 2020, by and among ClearPoint Neuro, Inc., each investor identified on the signature pages thereto, and Petrichor Opportunities Fund I LP, as collateral agent.

Exhibit 10.1 Execution Version SECOND OMNIBUS AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT AND SENIOR SECURED CONVERTIBLE NOTES This SECOND OMNIBUS AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT AND SENIOR SECURED CONVERTIBLE NOTES (this “Second Amendment”) is dated as of December 29, 2020 and is made in reference to that (i) certain Securities Purchase Agreement, dated as of January 11, 2020 (a

Form of Senior Secured Convertible Note (Second Closing).

Exhibit 4.1 THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO

ClearPoint Neuro, Inc. Announces Funding of Additional $7.5M of Existing Convertible Note on Improved Terms Represents Draw of Additional Proceeds from Petrichor Announced in January 2020

Exhibit 99.1 For Immediate Release ClearPoint Neuro, Inc. Announces Funding of Additional $7.5M of Existing Convertible Note on Improved Terms Represents Draw of Additional Proceeds from Petrichor Announced in January 2020 IRVINE, CA, December 29, 2020 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-34822 ClearP

ClearPoint Neuro Reports Third Quarter 2020 Results Revenue Reaches a Record $3.5 million

EX-99.1 2 ex99-1.htm CLEARPOINT NEURO REPORTS THIRD QUARTER 2020 RESULTS Exhibit 99.1 ClearPoint Neuro Reports Third Quarter 2020 Results Revenue Reaches a Record $3.5 million IRVINE, CA, November 10, 2020 – ClearPoint Neuro, Inc. (Nasdaq: CLPT), a medical device company with a portfolio of products focused on enabling therapies for neurological disorders, today announced financial results for its

Investor Presentation dated November 2020

Exhibit 99.2

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2020 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commissio

Transition Agreement, dated as of September 14, 2020, by and between the Company and Harold A. Hurwitz

Exhibit 10.1 THIS TRANSITION AGREEMENT (this “Agreement”) is entered into on this 14th day of September, 2020 (the “Effective Date”), by and between ClearPoint Neuro, Inc., a Delaware corporation (the “Company”), and Harold A. Hurwitz (“Hurwitz”). W I T N E S S E T H: WHEREAS, Hurwitz has served as the Chief Financial Officer and Secretary of the Company since May 8, 2015; WHEREAS, Hurwitz now des

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2020 ClearPoint Neuro, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commissi

Employment Agreement, dated as of September 14, 2020, by and between the Company and Danilo D’Alessandro

Exhibit 10.2 EMPLOYMENT AGREEMENT THIS AGREEMENT (this “Agreement”) is entered into as of this 14th day of September, 2020 (the “Effective Date”), by and between CLEARPOINT NEURO, INC., a Delaware corporation (the “Company”), and DANILO D’ALESSANDRO (the “Executive”). WITNESSETH: WHEREAS, the Company desires to employ the Executive to serve initially as the Vice President, Finance of the Company a

ClearPoint Neuro Announces Transition Plan for New Chief Financial Officer Danilo D’Alessandro will Succeed Harold A. Hurwitz who Plans to Retire in 2021

Exhibit 99.1 ClearPoint Neuro Announces Transition Plan for New Chief Financial Officer Danilo D’Alessandro will Succeed Harold A. Hurwitz who Plans to Retire in 2021 IRVINE, CA, September 14, 2020 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) is pleased to announce that global medical device financial executive Danilo D’Alessandro has been appointed the Company’s next Chief Financial Officer (CFO) succ

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-34822 ClearPoint

Regulation FD Disclosure, Results of Operations and Financial Condition -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2020 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission

Investor Presentation dated August 2020.

Exhibit 99.2

ClearPoint Neuro Reports Second Quarter 2020 Results Revenue Reaches $2.5 million Amid COVID-19 Pandemic

Exhibit 99.1 ClearPoint Neuro Reports Second Quarter 2020 Results Revenue Reaches $2.5 million Amid COVID-19 Pandemic IRVINE, CA, August 12, 2020 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) today announced financial results for its second fiscal quarter and six months ended June 30, 2020. Financial Results – Three Months Ended June 30, 2020 Total revenues for the quarter were approximately $2.5 millio

-

As filed with the Securities and Exchange Commission on June 3, 2020 Registration Statement No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

8-K 1 eps9081.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2020 (June 2, 2020) CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2020 CLEARPOINT NEURO, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission Fil

Investor Presentation dated May 2020.

Exhibit 99.1

Quarterly Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number: 001-34822 ClearPoint

ClearPoint Neuro Reports First Quarter 2020 Results Company Provides Update on Effects of COVID-19 Pandemic

Exhibit 99.1 ClearPoint Neuro Reports First Quarter 2020 Results Company Provides Update on Effects of COVID-19 Pandemic IRVINE, CA, May 12, 2020 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) today announced financial results for its first fiscal quarter ended March 31, 2020. Total revenues were approximately $3.1 million and $2.5 million for the three months ended March 31, 2020 and 2019, respectively,

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2020 ClearPoint Neuro, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission Fil

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2020 ClearPoint Neuro, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commission F

Third Amended and Restated 2013 Incentive Compensation Plan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2020 (April 16, 2020) ClearPoint Neuro, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorporati

BIOTECHNOLOGY LEADER AND SURGEON DR. MATTHEW KLEIN JOINS CLEARPOINT NEURO BOARD OF DIRECTORS

Exhibit 99.1 For Immediate Release BIOTECHNOLOGY LEADER AND SURGEON DR. MATTHEW KLEIN JOINS CLEARPOINT NEURO BOARD OF DIRECTORS IRVINE, CA, April 17, 2020 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) is pleased to announce that Matthew B. Klein, MD, MS, FACS, has been appointed to ClearPoint Neuro’s Board of Directors effective immediately. Dr. Klein, Chief Development Officer of PTC Therapeutics, Inc.

CLEARPOINT NEURO PROVIDES A COVID-19 PANDEMIC UPDATE AND ANNOUNCES PRELIMINARY FIRST QUARTER 2020 FINANCIAL RESULTS

EX-99.1 2 ex99-1.htm CLEARPOINT NEURO PROVIDES A COVID-19 PANDEMIC UPDATE AND ANNOUNCES PRELIMINARY FIRST QUARTER 2020 FINANCIAL RESULTS Exhibit 99.1 CLEARPOINT NEURO PROVIDES A COVID-19 PANDEMIC UPDATE AND ANNOUNCES PRELIMINARY FIRST QUARTER 2020 FINANCIAL RESULTS IRVINE, CA – April 16, 2020 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”) today provided an update with respect to the COVID

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 eps8982.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2020 ClearPoint Neuro, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorporat

Description of Securities

EXHIBIT 4.23 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ClearPoint Neuro, Inc. (“ClearPoint,” “we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, par value $0.01 per share (“Common Stock”). Authorized Shares o

Subsidiaries of MRI Interventions, Inc.

EXHIBIT 21 List of Subsidiaries Name of Subsidiary Jurisdiction of Formation MRI Interventions (Canada) Inc. Canada (New Brunswick)

MRIC / MRI Interventions Inc 10-K - Annual Report -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-34822 CLEARPOINT NEURO, INC.

Investor Presentation, dated February 2020

Exhibit 99.2

ClearPoint Neuro, Inc. Announces 2020 Revenue Outlook Ahead of Nasdaq Investor Presentation Today New U.S. and European Partnership Agreement with PTC Therapeutics Highlights Growth of ClearPoint® Gene Therapy Portfolio

EX-99 2 ex99-1.htm PRESS RELEASE Exhibit 99.1 For Immediate Release ClearPoint Neuro, Inc. Announces 2020 Revenue Outlook Ahead of Nasdaq Investor Presentation Today New U.S. and European Partnership Agreement with PTC Therapeutics Highlights Growth of ClearPoint® Gene Therapy Portfolio IRVINE, CA, February 14, 2020 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a leading platform neuros

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2020 ClearPoint Neuro, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commissio

MRIC / MRI Interventions Inc / SATTERFIELD THOMAS A JR - SC 13G/A Passive Investment

SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 3)* ClearPoint Neuro, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 55347P209 (CUSIP Number) December 31, 2019 (Date of Event Whic

MRI Interventions, Inc. Changes Corporate Name to ClearPoint Neuro, Inc. Company To Commence Trading Under Ticker Symbol CLPT on February 12, 2020

Exhibit 99.1 For Immediate Release MRI Interventions, Inc. Changes Corporate Name to ClearPoint Neuro, Inc. Company To Commence Trading Under Ticker Symbol CLPT on February 12, 2020 IRVINE, CA, February 11, 2020 – MRI Interventions, Inc. (Nasdaq: MRIC) (the “Company”), a leading platform neurosurgery company, will effectuate its previously announced change of its corporate name to ClearPoint Neuro

Second Amended and Restated Bylaws of ClearPoint Neuro, Inc.

Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF ClearPoint Neuro, INC. (the “Corporation”) ARTICLE I OFFICES 1.1 Registered Office. The address of the registered office of this Corporation in the State of Delaware is 1209 Orange Street, City of Wilmington, County of New Castle, Zip Code 19801, and the name of the registered agent of this Corporation in the State of Delaware at such address is Th

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2020 ClearPoint Neuro, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorporation) (Commissio

ClearPoint Neuro Reports 53% Increase in 2019 Revenue Fourth quarter revenue grows 41%, fifth consecutive quarter of revenue growth

Exhibit 99.1 ClearPoint Neuro Reports 53% Increase in 2019 Revenue Fourth quarter revenue grows 41%, fifth consecutive quarter of revenue growth IRVINE, CA, February 12, 2020 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (formerly, MRI Interventions, Inc.; the “Company”) today announced financial results for its fourth fiscal quarter and full year ended December 31, 2019. 2019 Full Year and Fourth Quart

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of ClearPoint Neuro, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, filed with the SEC on February 12, 2020).

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MRI INTERVENTIONS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware MRI INTERVENTIONS, INC., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: 1. Article I of the Amended a

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2020 (February 11, 2020) ClearPoint Neuro, Inc. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incor

Specimen of Common Stock Certificate of ClearPoint Neuro, Inc.

Exhibit 4.1

MRIC / MRI Interventions Inc / Ptc Therapeutics, Inc. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* MRI Interventions, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 55347P209 (CUSIP Number) Mark E. Boulding Executive Vice President and Chief Legal Officer PTC Therapeutics, Inc. 100 Corporate Court South Pl

Fourth Amendment to Junior Security Agreement, dated January 27, 2020, by and between MRI Interventions, Inc. and Landmark Community Bank, in its capacity as collateral agent

Exhibit 10.5 FOURTH AMENDMENT TO JUNIOR SECURITY AGREEMENT THIS FOURTH AMENDMENT TO JUNIOR SECURITY AGREEMENT (this “Fourth Amendment”) is made and entered as of January 27, 2020, by and between MRI INTERVENTIONS, INC., f/k/a SurgiVision, Inc., a Delaware corporation (the “Company”), and LANDMARK COMMUNITY BANK, a Tennessee state-chartered bank, in its capacity as collateral agent (the “Collateral

Fourth Omnibus Amendment to the Junior Secured Promissory Notes Due 2020, dated January 27, 2020

Exhibit 4.4 FOURTH OMNIBUS AMENDMENT TO THE JUNIOR SECURED PROMISSORY NOTES DUE 2020 This FOURTH OMNIBUS AMENDMENT (this “Fourth Amendment”) is dated as of January 27, 2020 and is made in reference to those certain Junior Secured Promissory Notes Due 2020, as amended (the “Junior Notes”), issued by MRI Interventions, Inc. (f/k/a SurgiVision, Inc.), a Delaware corporation (the “Company”), and payab

First OmnibusAmendment to Securities Purchase Agreement and Senior Secured Promissory Notes, dated January 29, 2020, by and among MRI Interventions, Inc., PTC Therapeutics, Inc., and Petrichor Opportunities Fund I LP

Exhibit 10.2 FIRST OMNIBUS AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT AND SENIOR SECURED CONVERTIBLE NOTES This FIRST OMNIBUS AMENDMENT TO THE SECURITIES PURCHASE AGREEMENT AND SENIOR SECURED CONVERTIBLE NOTES (this “First Amendment”) is dated as of January 29, 2020 and is made in reference to that (i) certain Securities Purchase Agreement, dated as of January 11, 2020 (the “Purchase Agreement

Board Observer Agreement, dated January 29, 2020, by and between MRI Interventions, Inc. and Petrichor Opportunities Fund I LP

Exhibit 10.4 BOARD OBSERVER AGREEMENT This Board Observer Agreement, dated as of January 29, 2020 (this “Agreement”), is entered into by and between MRI Interventions, Inc., a Delaware corporation (the “Company”), and Petrichor Opportunities Fund I LP (the “Investor”). Capitalized terms used but not otherwise defined herein shall have the meaning ascribed to such terms in the Purchase Agreement (d

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2020 (January 27, 2020) MRI INTERVENTIONS, INC. (Exact name of registrant as specified in its charter) DELAWARE 001-34822 58-2394628 (State or other jurisdiction of incorp